
Actimab-A Triplet Trial Launches in Frontline AML
The first clinical trial under the Cooperative Research and Development Agreement with the National Cancer Institute and Actinium Pharmaceuticals, Inc, for Actimab-A has been initiated (NCT06802523) and plans to evaluate the triplet combination of Actimab- …